Targets › SPPL3
1 program from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Feb 2027.
Intramembrane-cleaving aspartic protease (I-CLiP) that cleaves type II membrane protein substrates in or close to their luminal transmembrane domain boundaries. Acts like a sheddase by mediating the proteolytic release and secretion of active site-containing ectodomains of glycan-modifying glycosidase and glycosyltransferase enzymes such as MGAT5, B4GAT1 and B4GALT1. (UniProt, Q8TCT6)
Open in Phaseline: the race on SPPL3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Chinese PLA General Hospital | TCR reserved and Power3 (SPPL3) gene knock-out allogeneic CD19-targeting CAR-T c Allogeneic CAR-T cell therapy targeting CD19 with TCR alpha/beta chain (TRAC) and SPPL3 ge | TRBC, SPPL3, CD19, TCRA | Phase 1 | Acute Lymphocytic Leukemia; Non-hodgkin Lymphoma | Feb 2027 |
Acute Lymphocytic Leukemia (1) Non-hodgkin Lymphoma (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.